Journal of Psychiatry

Abstract

Null Hypothesis Proven in Sebum Infectant to Immune Reflex through Sebaceous Immunobiology by COVID-19 Vaccine

Yang I. Pachankis*

Background: The completed interventional trial was conceived from the phenomena of COVID-19 (Coronavirus Disease 2019) post-vaccination adverse events. The accumulated evidence has proven the null hypothesis with significant results that falsify the predominant belief in the vaccination method. The alternative hypothesis is adjusted with proton equilibrium and sebaceous immunobiology’s correlations with immune reflex.

Methods: The sole-participant interventional trial compared the main medicines in myocarditis treatment from Nifedipine to Angiotensin-Converting Enzyme Inhibitor (ACEI) and Angiotensin Receptor-Neprilysin Inhibitor (ANRI) with increasing power level. T values and Z statistics are calculated for statistical analysis, and the introduction of proton-pump inhibitor is uncertain with the case’s neurodivergent conditions.

Result: Inter-ACEI comparison suggests the introduction of beta blockers regulated the immune reflex through heart rate with the blood-borne pathogen. ANRI superiority suggests S2 pathogens can be more severe without S1 constraints, and raises alerts on SARS-CoV-2 (Severe Acute Respiratory Syndrome-Coronavirus-2) mutational directions from Omicron. Historic data from the participant after the second COVID-19 vaccine shot recorded the viral entry through Low-Density Lipoprotein Cholesterol (LDL-C).

Discussion: The study protocol with data refers to SARS-CoV-2’s S2 infection concentration and viral characteristics in LDL-C in human host. It is highly probable that S2 pathogen starts with LDL-C in vaccine poisoning. It is possible that HDL-C levels are responsible for the cytokine storms in neurologically infected cases. The placebo effect is maximized by the vaccine mandates, and the mass psychological biases need time to be narrowed down.

Trial registration: The study protocol is registered on ClinicalTrials.gov with the identifier number NCT05711810. Following trial on the hypothalamic-pituitary-adrenal axis is registered with the identifier number NCT05930912.

Published Date: 2023-08-11; Received Date: 2023-07-12